Colon, Rectal, and Anal Cancers

Suggested Reading

On Colorectal Carcinoma

Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin(Drug information on oxaliplatin), fluorouracil(Drug information on fluorouracil), and leucovorin with or without cetuximab(Drug information on cetuximab) on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307:1383–1393, 2012.

Allegra CJ, Yothers G, O'Connell MJ, et al: Phase III trial assessing bevacizumab(Drug information on bevacizumab) in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 29:11–16, 2011.

André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116, 2009.

Atkin WS, Edwards R, Kralj-Hans I, et al: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: A multicentre randomised controlled trial. Lancet 375:1624–1633, 2010.

Bernstein TE, Endreseth BH, Romundstad P, et al: Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 96:1348–1357, 2009.

Braendengen M, Tveit KM, Berglund A, et al: Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26:3687–3694, 2008.

Fazio VW, Zutshi M, Remzi FH, et al: A randomized multicenter trial to compare long-term functional outcome, quality of life, and complications of surgical procedures for low rectal cancers. Ann Surg 246:481–488, 2007.

Fleshman J, Sargent DJ, Green E, et al: Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg 246:655–662, 2007.

Garcia-Aguilar J, Shi Q, Thomas CR Jr, et al: Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial. J Clin Oncol 28(15S):abstract 3510, 2010.

Greenberg JA, Shibata D, Herndon JE 2nd, et al: Local excision of distal rectal cancer: An update of cancer and leukemia group B 8984. Dis Colon Rectum 51:1185–1191, 2008.

Haller DG, Tabernero J, Maroun J, et al: Capecitabine(Drug information on capecitabine) plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465–1471, 2011.

Hofheinz RD, Wenz F, Post S, et al: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13:579–588, 2012.

Jayne DG, Guillou PJ, Thorpe H, et al: Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol 25:3061–3068, 2007.

Jimeno A, Messersmith WA, Hirsch FR, et al: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection. J Clin Oncol 27:1130–1136, 2009.

Kim DH, Pickhardt PJ, Taylor AJ, et al: CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med 357:1403–1412, 2007.

Leung KL, Kwok SP, Lam SC, et al: Laparoscopic resection of rectosigmoid carcinoma: Prospective randomised trial. Lancet 363:1187–1192, 2004.

Levin B, Lieberman DA, McFarland B, et al: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58:130–160, 2008.

Marijnen CA, van Gijn W, Nagtegaal ID, et al: The TME trial after a median follow-up of 11 years. Presented at: 52nd Annual ASTRO Meeting; November 1, 2010; San Diego, CA. Abstract 1.

Olivatto LO, Araujo CM, Vilhena B, et al: Phase I study of cetuximab in combination with 5-FU, cisplatin, and radiotherapy in patients with locally advanced squamous cell anal canal carcinoma. Presented at: ASCO 2010 Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, FL. Abstract 492.

Papamichael D, Audisio R, Horiot JC, et al: Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 20:5–16, 2009.

Park IJ, You YN, Agarwal A, et al: Neoadjuvant treatment response as an early response indicator for rectal cancer. J Clin Oncol 30:1770–1776, 2012.

Peeters KC, Marijnen CA, Nagtegaal ID, et al: The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701, 2007.

Poultsides GA, Servais EL, Saltz LB, et al: Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379–3384, 2009.

Roh MS, Colangelo LH, O'Connell MJ, et al: Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124–5130, 2009.

Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 29(suppl):abstract 3503, 2011.

Sauer R, Liersch T, Merkel S, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926–1933, 2012.

Sebag-Montefiore D, Stephens RJ, Steele R, et al: Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet 373:811–820, 2009.

Segnan N, Armaroli P, Bonelli L, et al: Once-only sigmoidoscopy in colorectal cancer screening: Follow-up findings of the Italian Randomized Controllled Trial—SCORE. J Natl Cancer Inst 103:1310–1322, 2011.

Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236, 2011.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308–1324, 2009.

Sinicrope FA, Sargent DJ: Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21:369–373, 2009.

Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–572, 2009.

Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417, 2009.

Van Cutsem E, Labianca R, Bodoky G, et al: Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan(Drug information on irinotecan) in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117–3125, 2009.

You YN, Baxter NN, Stewart A, Nelson H: Is the increasing rate of local excision for stage I rectal cancer in the United States justified? A nationwide cohort study from the National Cancer Database. Ann Surg 245:726–733, 2007.

On Anal Canal Carcinoma

Ajani JA, Winter KA, Gunderson LL, et al: Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 299:1914–1921, 2008.

Das P, Bhatia S, Eng C, et al: Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 68:794–800, 2007.

Eng C, Crane CH, Rodriguez-Bigas MA: Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal? Nat Clin Pract Gastroenterol Hepatol 6:16–17, 2009.

Ghouti L, Houvenaeghel G, Moutardier V, et al: Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum 48:16–22, 2005.

Kachnic LA, Winter KA, Myerson RJ, et al: RTOG 0529: A phase II study of dose-painted IMRT (DP-IMRT), 5-fluorouracil, and mitomycin-C for the reduction of acute morbidity in anal cancer. ASCO 2010 Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, FL. Abstract 405.

Mullen JT, Rodriguez-Bigas MA, Chang GJ, et al: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 14:478–483, 2007.

Podnos YD, Tsai NC, Smith D, Ellenhorn JD: Factors affecting survival in patients with anal melanoma. Am Surg 72:917–920, 2006.

Salama JK, Mell LK, Schomas DA, et al: Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience. J Clin Oncol 25:4581–4586, 2007.

Vuong T, Kopek N, Ducruet T, et al: Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys 67:1394–1400, 2007.